ESMO 2025: Treatment with CDK4/6 Inhibitors Extending Their Benefit and Reinforcing the Value for Patients with High-Risk HR+, HER2-Negative Early Breast Cancer
Updated long-term follow-up data presented at ESMO 2025 reinforce the sustained benefit of adjuvant CDK4/6 inhibitors in patients with high-risk hormone receptor-positive (HR+), HER2-negative early breast cancer.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
